Dutch biotech Pharming plans to challenge big pharma in rare diseasesThe introduction of Shire’s preventive treatment for hereditary angioedema has shaken up the market for drugs for this Share XDutch biotech Pharming plans to challenge big pharma in rare diseaseshttps://pharmaphorum.com/r-d/views-analysis-r-d/pharming-challenge-pharma-rare-diseases/
AZ and CRUK team up to go all-in on CRISPRAstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling Share XAZ and CRUK team up to go all-in on CRISPRhttps://pharmaphorum.com/news/az-cruk-crispr/
Moderna shares slide after record $604m US listingRNA drug specialist Moderna smashed the record for an initial public offering (IPO) in the US on Friday, Share XModerna shares slide after record $604m US listinghttps://pharmaphorum.com/news/moderna-shares-slide-after-record-604m-us-listing/
Supernus says ADHD drug trounces rivals, but shares slideSupernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, Share XSupernus says ADHD drug trounces rivals, but shares slidehttps://pharmaphorum.com/news/supernus-says-adhd-drug-trounces-rivals-but-shares-slide/
Four steps for more patient centric trialsMedidata’s general manager & senior vice president EMEA, Christian Hebenstreit, on placing the patient experience at the heart Share XFour steps for more patient centric trialshttps://pharmaphorum.com/r-d/views-analysis-r-d/four-steps-patient-centric-trials/
After delayed IPO, Mereo gets US listing via OncoMed mergerUK biotech Mereo BioPharma is merging with Californian biotech OncoMed in an all-stock deal that swells its pipeline Share XAfter delayed IPO, Mereo gets US listing via OncoMed mergerhttps://pharmaphorum.com/news/after-delayed-ipo-mereo-gets-us-listing-via-oncomed-merger/
Novartis takes Xolair follow-up into phase III hives trialNovartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, Share XNovartis takes Xolair follow-up into phase III hives trialhttps://pharmaphorum.com/news/novartis-takes-xolair-follow-up-into-phase-iii-hives-trial/
Is the pharma gender gap starting to close?When Emma Walmsley took the reins of GlaxoSmithKline (GSK) in 2016, becoming the first woman to head up Share XIs the pharma gender gap starting to close?https://pharmaphorum.com/views-analysis-sales-marketing/is-the-pharma-gender-gap-starting-to-close/
Beckley Canopy Therapeutics raises £7.4m for cannabis R&DOxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the Share XBeckley Canopy Therapeutics raises £7.4m for cannabis R&Dhttps://pharmaphorum.com/news/beckley-canopy-therapeutics-raises-7-4m-for-cannabis-rd/
